Financial Data and Key Metrics Changes - Backlog reached a record $19.9 million, an increase of $12.4 million and 165% year-over-year [10] - Pipeline expanded to $163.9 million, up $74.7 million and 84% year-over-year [10] - Revenue for Q3 2026 was $0.5 million, down from $0.8 million in Q3 2025; revenue for the nine months ended January 31, 2026, was $2.1 million, down from $4.5 million in the same period last year [11] - Gross profit for Q3 2026 was a loss of $0.8 million, compared to a gross profit of $0.2 million in Q3 2025 [12] - Net losses for Q3 2026 were $11.4 million, compared to $6.7 million in Q3 2025 [13][14] Business Line Data and Key Metrics Changes - Significant portion of the pipeline is associated with defense and security programs, indicating a strategic focus on these areas [4] - The company is advancing its integrated autonomous docking and charging solution, transitioning from prototype to full-scale build [5] - The operational data accumulated from real-world maritime environments is enhancing mission readiness and informing product improvements [7] Market Data and Key Metrics Changes - The company is expanding its global operational footprint, with shipments to Greece and ongoing customer operations in international defense and commercial markets [5] - Approximately half of the backlog is from North America, with the remainder split between Latin America and parts of the Middle East [20] Company Strategy and Development Direction - The company aims to enable autonomous systems to operate persistently offshore, supporting long-duration missions without traditional logistics [5] - The strategy focuses on building a global maritime autonomy infrastructure layer, positioning the company as a platform provider rather than just a product provider [8] - Continued engagement with government and commercial customers is expected to drive future growth [15] Management's Comments on Operating Environment and Future Outlook - Management noted strong demand signals across core markets, with backlog and pipeline levels significantly higher than a year ago [15] - The organization is aligned to support growth, focusing on execution, reliability, and delivering consistent solutions [16] Other Important Information - The company has a cash position of $7.2 million as of January 31, 2026, compared to $6.9 million at the beginning of the fiscal year [14] - Operating expenses increased due to higher non-cash stock-based compensation and increased headcount to strengthen competitive position [12][13] Q&A Session Summary Question: Visibility on backlog delivery cadence and categorization by geography or customer type - Management confirmed that a portion of the $19.9 million backlog is due for immediate delivery, with contracts for the Department of Homeland Security expected to start recognizing revenue soon [18][19] Question: Prospects for contracts in UAE waters - Management stated that assets are in the country and local staff are working on supporting shipping and safe port operations [22] Question: Inclusion of recurring revenues from Merrows in backlog - Management clarified that while there are no specific Merrows contracts, the Homeland Security contract utilizes the Merrows platform for data streaming [23][24] Question: Expectations for positive gross margins going forward - Management indicated that improvements in gross margins are expected as larger scale deployments are initiated [26] Question: Competition for potential orders and confidence in pipeline conversion - Management expressed confidence in the conversion of the $164 million pipeline to backlog, citing a well-positioned team and less competition in their market segment [27][28] Question: Status of defense engagements in Latin America - Management reported ongoing exercises in Latin America and discussions for deploying buoys for surveillance operations [33][34] Question: Inventory strategy and pre-build activity - Management confirmed that inventory growth reflects pre-building buoys to accelerate delivery and that this strategy will continue [35] Question: Expansion beyond Coast Guard into other DHS components - Management highlighted that their team’s clearance enables participation in discussions with various DHS components, positioning them for future opportunities [36]

Ovid Therapeutics (NasdaqGS:OVID) Q4 2025 Earnings call March 18, 2026 08:30 AM ET Company ParticipantsAlyssa Larios - Senior Associate in Equity ResearchJeffrey Rona - Chief Business and Financial OfficerMeg Alexander - President and CEOVictoria Fort - SVP of Corporate Affairs and Corporate StrategyConference Call ParticipantsFrançois Brisebois - Managing Director in Equity Research and Senior Biotechnology AnalystJay Olson - Managing Director in Equity Research and Senior Biotechnology AnalystLaura Chico ...

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, was $22 million, a decrease of approximately 14% from $25.7 million in 2024 [17] - Gross profit increased to $8.4 million or 38.2% of revenue compared to $8.2 million or 32% of revenue in 2024 [19] - Operating expenses declined by 25% to $28.1 million in 2025 compared to $37.6 million in 2024 [20] - Net loss narrowed by 31% to $19.9 million in 2025 compared to $28.9 million in 2024 [22] Business Line Data and Key Metrics Changes - Revenue from ReWalk Personal Exoskeleton was relatively flat at $8.5 million in 2025 compared to $8.9 million in 2024, with units sold increasing by 22% year-over-year [17] - Revenue from MyoCycle FES bike declined by 50% to $600,000, reflecting a strategic focus on core products [18] - Revenue from AlterG products and services was $12.9 million, an 18% decline from 2024, primarily due to lower international sales [18] Market Data and Key Metrics Changes - Reimbursement coverage for ReWalk expanded to include three largest Medicare Advantage insurers in the U.S., covering over 16 million lives [13] - International distribution efforts accelerated following the receipt of CE mark, with Germany as the primary test market [13] Company Strategy and Development Direction - The company is executing a strategy to build a diversified biomedical innovation company with multiple technology platforms [3] - A strategic transaction with Oramed is expected to strengthen the financial foundation and expand strategic scope [4] - Focus on cash flow positive operations while investing in innovations that will define the future of the company [3][25] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about growth in the core med tech business and improvements in operating expenses [15] - The company is focused on building a strong payer engagement capability to expand patient access and accelerate adoption of technologies [11] Other Important Information - The company plans to increase investment in R&D as new products advance to market, including the upper body exoskeleton [21] - A $3 million loan agreement with Oramed was entered into for additional capital support [23] Q&A Session Questions and Answers Question: How does the Oramed POD technology align with the company's current infrastructure? - Management indicated that the integration of Oramed's technology would drive synergies across med tech and biotech, enhancing the company's decentralized approach to commercialization [27][28] Question: What is the timeline for the upper extremity robotic assistance product? - Management stated that the product could be a 510(k) exempt product, with a timeline of 18-24 months for commercialization [32][33] Question: How should investors view the company's diversification into biotech? - Management emphasized that a diversified portfolio in med tech and biotech is beneficial, providing multiple opportunities for product commercialization [42][43]

Financial Data and Key Metrics Changes - The company achieved an annual recurring revenue (ARR) of $1.125 billion, representing a 28% year-over-year growth, which is consistent with the growth rate maintained over the past three quarters [20][25] - SaaS ARR reached $746 million, reflecting a 38% year-over-year increase and accounting for 90% of net new ARR in fiscal Q4 [21][25] - The adjusted operating margin for Q4 was 20.6%, an expansion of 160 basis points year-over-year, while the annual adjusted operating margin was 18.1%, an increase of 270 basis points [25][27] Business Line Data and Key Metrics Changes - Net new ARR from emerging products more than doubled quarter-over-quarter, contributing approximately 17% of net new ARR in fiscal Q4 [22] - The average ARR per SaaS customer grew to over $380,000, a 19% increase from the previous year [22] - The company closed the fiscal year with 215 customers exceeding $1 million in ARR, a 34% increase from the previous year [23] Market Data and Key Metrics Changes - Non-human identities accounted for approximately 25% of SaaS identity growth in Q4 and now represent 11% of SaaS identities under governance [14] - The company noted a significant opportunity for growth as existing perpetual and term license customers represent approximately $350 million in ARR, with a typical 2-3x uplift upon migration [24] Company Strategy and Development Direction - The company aims to deepen its footprint within existing customers while attracting new customers, leveraging its SaaS-first strategy and AI-powered platform [16][17] - The focus is on defining a new standard of adaptive identity governance, emphasizing real-time governance and least privilege access [17][18] - The company is positioned as a foundational security control plane for the modern AI-powered enterprise, capitalizing on the growing demand for identity security solutions [10][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the evolving market landscape, particularly with the rise of AI and non-human identities [10][46] - The company anticipates FY 27 to be the year of AI adoption, with a strong pipeline and healthy demand for its identity security platform [16][20] - Management emphasized the importance of domain knowledge and the ability to leverage AI technologies to enhance customer security and operational efficiency [81] Other Important Information - The company generated $64 million in cash from operating activities and $57 million in free cash flow, representing a 19.5% free cash flow margin [25] - The guidance for FY 2027 includes an expected ARR of $1.361 billion, up 21% year-over-year, and revenue of approximately $1.265 billion, an 18% increase year-over-year [27] Q&A Session Summary Question: ARR guidance for fiscal 2027 - Management indicated strong momentum heading into the year, with a focus on prudent guidance despite healthy demand and a strong pipeline [31][32] Question: Impact of new pricing models on customer engagement - Management noted that new pricing models have shown significant uptake, contributing to strong migration and customer engagement [39] Question: Market expansion drivers and future growth - Management highlighted the significant market expansion driven by the rise of non-human identities and the need for adaptive identity security solutions [45][46] Question: Changes in sales cycles due to non-human identities - Management acknowledged that sales cycles have elongated slightly but did not see any recent changes that would alter this trend [94]

Financial Data and Key Metrics Changes - As of December 31, 2025, Ovid Therapeutics reported $90.4 million in cash equivalents and marketable securities [42] - The company announced a PIPE financing with gross proceeds totaling $60 million, which is expected to extend the cash runway into the second half of 2028 [42] - If the Series A warrants are fully exercised, the pro forma cash runway could extend well into 2029 [42] Business Line Data and Key Metrics Changes - The company received regulatory clearance for OV4071, the first-ever oral KCC2 direct activator, a quarter earlier than expected [5] - OV329, a next-generation GABA aminotransferase inhibitor, has shown no serious adverse events at the 7-milligram dose, indicating a strong safety and tolerability profile [5][13] - The company is launching additional studies for OV329 in infantile spasms and seizures associated with tuberous sclerosis complex, supported by new capital [7][8] Market Data and Key Metrics Changes - The market opportunity for OV329 is significant, especially in treating conditions like infantile spasms and tuberous sclerosis complex, where current treatment options are limited [24][27] - The peak sales of Sabril (Vigabatrin) reached over $320 million, indicating a substantial market potential for a safer alternative like OV329 [79] Company Strategy and Development Direction - Ovid Therapeutics aims to develop gentler, better medicines for the brain, focusing on controlling neural hyperexcitability through small molecule programs [9] - The company plans to initiate a phase 1 study for OV4071 and a ketamine challenge study to demonstrate proof of mechanism [33][40] - The strategy includes developing differentiated formulations for adult and pediatric populations, allowing for differential pricing based on the specific needs of each community [70] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of OV329 to be used earlier and longer in treatment, which could change the trajectory of diseases for children with severe conditions [78] - The company is optimistic about the upcoming milestones and catalysts, indicating a busy couple of years ahead [37] Other Important Information - Ovid Therapeutics does not plan to host regular quarterly earnings calls moving forward, indicating a shift in communication strategy [4] - The company is preparing for a KCC2 day to provide more insights into the KCC2 portfolio and its therapeutic potential [36] Q&A Session Summary Question: Can you provide more detail on OV329 and the visual monitoring? - Management confirmed that optic and retinal monitoring will continue through phase 2 and pivotal studies to ensure robust safety data [50] Question: What are the key endpoints for the planned phase two design for OV329? - The phase 2 study will target adults with treatment-resistant focal onset seizures, focusing on traditional endpoints like percent reduction in seizures and CGI endpoints [59] Question: What type of patients will be enrolled in the open-label photosensitive epilepsy study? - The study will enroll adults with diagnosed epilepsy and documented photosensitivity, using intermittent photic stimulation for screening [67] Question: How does the company plan to address long-term clinical development for OV329? - Management indicated that OV329 has broad therapeutic utility and that evidence will inform potential expansions into other indications [91]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $3.1 million, a 62% increase from $1.9 million in Q4 2024, driven by the U.S. launch of CGuard Prime and increased international market penetration [10] - U.S. revenue for Q4 was $866,000, representing a 74% sequential growth compared to Q3 2025 [10] - International revenue for Q4 was $2.3 million, reflecting a 17% growth compared to $1.9 million in Q4 2024 [10] - Gross profit for Q4 2025 was $1.2 million, or 37.5% of revenue, up from $469,000 or 24.1% of revenue in Q4 2024, primarily due to a favorable shift in revenue mix towards U.S. sales [11] - Net loss for Q4 2025 was $11.8 million, or $0.14 per share, compared to a net loss of $9.2 million or $0.19 per share in Q4 2024 [13] Business Line Data and Key Metrics Changes - The company has completed over 500 cases and gained approvals in prominent Integrated Delivery Networks (IDNs) in the U.S. [6] - The CGuard stent has been used in over 70,000 cases across 30 international markets, providing valuable real-world experience for the U.S. launch [6] Market Data and Key Metrics Changes - The company anticipates revenue for the full year 2026 to be in the range of $13 million to $15 million, reflecting a growth of approximately 45% to 65% over 2025 [15] - The company expects increasing sequential revenue growth in the second half of 2026, driven by anticipated FDA label expansion for CGuard Prime in TCAR procedures [16] Company Strategy and Development Direction - The company aims to achieve market leadership through a stent-first strategy, focusing on operational expansion and establishing U.S.-based production to meet growing demand [4][5] - The company is committed to continuous improvement of its products and plans to introduce enhancements to the delivery system in Q4 2026 [7][25] Management's Comments on Operating Environment and Future Outlook - Management expressed enthusiasm about the company's impact on stroke prevention and the future of endovascular care, emphasizing the importance of operational and commercial excellence [4] - The management highlighted the positive trajectory of the U.S. launch and the anticipated progress in 2026 [10][15] Other Important Information - Cash and cash equivalents and marketable securities were $54.2 million as of December 31, 2025, compared to $34.6 million at the end of the previous year [14] - The company has two remaining milestone-based tranches from a private placement, each providing gross proceeds of $17.9 million if fully exercised [14] Q&A Session Summary Question: Guidance for FY 2026 - The management expects moderate growth in OUS sales and sustained controlled launch in the U.S. for the first half, with acceleration in the second half due to anticipated TCAR indication and enhanced clinical performance [19][20] Question: Account Standpoint in the U.S. - The company has completed cases in roughly 80 centers, with over 200 centers in the pipeline for VAC and evaluation stages [23] Question: Next Generation Delivery System - The next generation delivery system is targeted for Q4 2026, with minor regulatory changes expected to go through a 30-day FDA review [25][27] Question: Timing for CGUARDIANS II Data - The first reveal of CGUARDIANS II data is expected at the Charing Cross Symposium in April [30] Question: Account Adoption and Productivity Metrics - The company aims for CGuard to become the everyday stent for physicians, with a focus on increasing account adoption and productivity [34][35]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $3.1 million, a 62% increase from $1.9 million in Q4 2024, driven by the U.S. launch of CGuard Prime and increased international market penetration [10] - U.S. revenue for Q4 was $866,000, representing a 74% sequential growth compared to Q3 [10] - International revenue for Q4 was $2.3 million, reflecting a 17% growth compared to $1.9 million in Q4 2024 [10] - Gross profit for Q4 2025 was $1.2 million, or 37.5% of revenue, up from $469,000 or 24.1% of revenue in Q4 2024, primarily due to a favorable shift in revenue mix towards U.S. sales [11] - Net loss for Q4 2025 was $11.8 million, or $0.14 per share, compared to a net loss of $9.2 million or $0.19 per share in Q4 2024 [13] Business Line Data and Key Metrics Changes - The CGuard Prime stent platform has been launched in the U.S., with over 500 cases completed and approvals gained in prominent Integrated Delivery Networks (IDNs) [6] - The company has built a U.S. commercial team of over 30 people, focusing on operational expansion and increasing manufacturing capacity [5] Market Data and Key Metrics Changes - The company is focusing on expanding its market presence in the U.S. and international markets, with a strategy to dominate the carotid stenting space [4] - The anticipated FDA approval for TCAR indications is expected to boost market opportunities significantly [8] Company Strategy and Development Direction - The company aims to achieve market leadership through a stent-first strategy, focusing on operational excellence and customer support [4] - Plans include expanding the clinical pipeline and advancing indications for CGuard, with multiple programs and studies underway [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of U.S. sales and anticipates continued progress in 2026, with revenue expected to be between $13 million and $15 million, reflecting a growth of approximately 45%-65% over 2025 [15] - The company is committed to continuous improvement and exceeding customer expectations, with plans to introduce enhancements to the delivery system in Q4 2026 [26] Other Important Information - Cash and cash equivalents and marketable securities were $54.2 million as of December 31, 2025, compared to $34.6 million at the end of the previous year [14] - The company has two remaining milestone-based tranches from a private placement, each providing gross proceeds of $17.9 million if fully exercised [14] Q&A Session Summary Question: Guidance for FY 2026 - Management expects moderate growth in OUS sales and acceleration in U.S. growth in the second half of 2026 due to anticipated TCAR indication and enhanced clinical performance [19][20] Question: Account Standpoint in the U.S. - Cases have been performed in roughly 80 centers, with over 200 centers in the pipeline for VAC and evaluation stages [23] Question: Next Generation Delivery System - The next generation delivery system is targeted for Q4 2026, with minor regulatory changes expected to go through a 30-day FDA review [26] Question: Timing for CGUARDIANS II Data - CGUARDIANS II data will be first revealed at the Charing Cross Symposium in April, likely as an interim cut [30] Question: Account Adoption and Productivity Metrics - A growing number of physicians are using CGuard as their everyday stent, with an average of 15-20 cases per physician per year [35]

Jabil (NYSE:JBL) Q2 2026 Earnings call March 18, 2026 08:30 AM ET Company ParticipantsAdam Berry - SVP of Investor Relations and Corporate AffairsGregory Hebard - CFO and EVPMichael Dastoor - CEOSteven Fox - Founder and CEOConference Call ParticipantsDavid Vogt - Managing Director and Equity Research AnalystLuke Junk - Senior Research AnalystMark Delaney - Equity Research AnalystMelissa Fairbanks - VP and Equity Research AnalystRuplu Bhattacharya - Director and Equity Research AnalystSamik Chatterjee - Mana ...

Spire Global (NYSE:SPIR) Q4 2025 Earnings call March 18, 2026 08:30 AM ET Company ParticipantsAlison Engel - CFOAustin Moeller - Director of Equity ResearchBenjamin Hackman - Head of Investor RelationsErik Rasmussen - VPTheresa Condor - CEOConference Call ParticipantsBrian Kinstlinger - Director of Research and Senior Technology AnalystJeff Van Rhee - Senior Research AnalystScott Buck - Managing Director and Equity Research Analyst of TechnologyOperatorGreetings, and welcome to the Spire Global fourth quart ...

SailPoint (NasdaqGS:SAIL) Q4 2026 Earnings call March 18, 2026 08:30 AM ET Company ParticipantsAnnick Baumann - VP of Equity ResearchBrian Carolan - CFOBrian Essex - Executive Director and U.S. Software Equity ResearchGabriela Borges - Managing Director and Head of U.S. Software Equity ResearchMark McClain - CEO and FounderMatt Mills - President of Worldwide Field OperationsScott Schmitz - SVP of Investor RelationsConference Call ParticipantsGray Powell - Managing Director and BTIG Security and Infrastructu ...